Body Mass Index and Antibody Persistence after Measles, Mumps, Rubella and Hepatitis B Vaccinations
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion Criteria
2.2. Population
2.3. Antibody Measurements
2.4. Statistics and Participants’ Informed Consent
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO. Obesity and Overweight. Genève (CH). Available online: https://www.who.int/news-room/fact-sheets (accessed on 13 September 2021).
- Bray, G.A. Medical Consequences of Obesity. J. Clin. Endocrinol. Metab. 2004, 89, 2583–2589. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Powell-Wiley, T.M.; Poirier, P.; Burke, L.E.; Després, J.P.; Gordon-Larsen, P.; Lavie, C.J.; Lear, S.A.; Ndumele, C.E.; Neeland, I.J.; Sanders, P.; et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation 2021, 143, e984–e1010. [Google Scholar] [CrossRef] [PubMed]
- Dhurandhar, N.V.; Bailey, D.; Thomas, D. Interaction of obesity and infections. Obes. Rev. 2015, 16, 1017–1029. [Google Scholar] [CrossRef] [PubMed]
- Khafagy, A.; AlJahdaly, I.; Goweda, R. Hepatitis B Vaccine: Assessment of Immunologic Response, Coverage Rate, and Factors Influencing Seroreactivity. Clin. Lab. 2020, 66. [Google Scholar] [CrossRef]
- Painter, S.D.; Ovsyannikova, I.G.; Poland, G.A. The weight of obesity on the human immune response to vaccination. Vaccine 2015, 33, 4422–4429. [Google Scholar] [CrossRef][Green Version]
- Fernández-Real, J.M.; Ferri, M.J.; Vendrell, J.; Ricart, W. Burden of infection and fat mass in healthy middle-aged men. Obesity 2007, 15, 245–252. [Google Scholar] [CrossRef][Green Version]
- Twig, G.; Geva, N.; Levine, H.; Derazne, E.; Goldberger, N.; Haklai, Z.; Leiba, A.; Kark, J.D. Body mass index and infectious disease mortality in midlife in a cohort of 2.3 million adolescents. Int. J. Obes. 2018, 42, 801–807. [Google Scholar] [CrossRef]
- Cocoros, N.M.; Lash, T.L.; Nørgaard, M.; Farkas, D.K.; DeMaria, A., Jr.; Sørensen, H.T. Hospitalized prenatal and childhood infections and obesity in Danish male conscripts. Ann. Epidemiol. 2013, 23, 307–313. [Google Scholar] [CrossRef]
- McMahon, B.J.; Bruden, D.L.; Petersen, K.M.; Bulkow, L.R.; Parkinson, A.J.; Nainan, O.; Khristova, M.; Zanis, C.; Peters, H.; Margolis, H.S. Antibody levels and protection after hepatitis B vaccination: Results of a 15-year follow-up. Ann. Intern. Med. 2005, 142, 333–341. [Google Scholar] [CrossRef]
- Lau, Y.L. Hepatitis B vaccination in preterm infants. Pediatr. Infect. Dis. J. 1994, 13, 243. [Google Scholar] [CrossRef]
- Alimonos, K.; Nafziger, A.N.; Murray, J.; Bertino, J.S., Jr. Prediction of response to hepatitis B vaccine in health care workers: Whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness. Clin. Infect. Dis. 1998, 26, 566–571. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Marinho, R.T.; Moura, M.C.; Pedro, M.; Ramalho, F.J.; Velosa, J.F. Hepatitis B vaccination in hospital personnel and medical students. J. Clin. Gastroenterol. 1999, 28, 317–322. [Google Scholar] [CrossRef]
- Chiara, F.; Bartolucci, G.B.; Mongillo, M.; Ferretto, L.; Nicolli, A.; Trevisan, A. Hepatitis B vaccination at three months of age: A successful strategy? Vaccine 2013, 31, 1696–1700. [Google Scholar] [CrossRef]
- Trevisan, A.; Mason, P.; Nicolli, A.; Maso, S.; Fonzo, M.; Scarpa, B.; Bertoncello, C. Future Healthcare Workers and Hepatitis B Vaccination: A New Generation. Int. J. Environ. Res. Public Health 2021, 18, 7783. [Google Scholar] [CrossRef]
- Ministero della Salute. Circolare n. 12. Controllo ed Eliminazione di Morbillo, Parotite e Rosolia per Mezzo Della Vaccinazione (Circular 12. Control and Elimination of Measles, Mumps and Rubella by Means of Vaccination); Ministry of Health: Rome, Italy, 13 July 1999.
- Decreto Presidente Consiglio dei Ministri. Piano Nazionale per L’eliminazione del Morbillo e Della Rosolia Congenita (Presidential Decree of the Council of Ministers. National Plan for the Elimination of Measles and Congenital Rubella); Presidency of the Council: Rome, Italy, 29 November 2001.
- Centers for Disease Control and Prevention. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999, 48, 1–5. [Google Scholar]
- Weber, D.J.; Rutala, W.A.; Samsa, G.P.; Santimaw, J.E.; Lemon, S.M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985, 254, 3187–3189. [Google Scholar] [CrossRef] [PubMed]
- Weber, D.J.; Rutala, W.A.; Samsa, G.P.; Bradshaw, S.E.; Lemon, S.M. Impaired immunogenicity of hepatitis B vaccine in obese persons. N. Engl. J. Med. 1986, 314, 1393. [Google Scholar] [PubMed]
- Corrao, G.; Calleri, M.; Zotti, M.; Barral, C.; Russo, R.; Garella, D.; Moiraghi Ruggenini, A. Immune response to anti-HBV vaccination: Study of conditioning factors. Eur. J. Epidemiol. 1988, 4, 492–496. [Google Scholar] [CrossRef] [PubMed]
- Roome, A.J.; Walsh, S.J.; Cartter, M.L.; Hadler, J.L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993, 270, 2931–2934. [Google Scholar] [CrossRef]
- Wood, R.C.; MacDonald, K.L.; White, K.E.; Hedberg, C.W.; Hanson, M.; Osterholm, M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993, 270, 2935–2939. [Google Scholar] [CrossRef]
- Simó Miñana, J.; Gaztambide Ganuza, M.; Fernández Millán, P.; Peña Fernández, M. Hepatitis B vaccine immunoresponsiveness in adolescents: A revaccination proposal after primary vaccination. Vaccine 1996, 14, 103–106. [Google Scholar] [CrossRef]
- Goldwater, P.N. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997, 15, 353–356. [Google Scholar] [CrossRef]
- Averhoff, F.; Mahoney, F.; Coleman, P.; Schatz, G.; Hurwitz, E.; Margolis, H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am. J. Prev. Med. 1998, 15, 1–8. [Google Scholar] [CrossRef]
- Ingardia, C.J.; Kelley, L.; Steinfeld, J.D.; Wax, J.R. Hepatitis B vaccination in pregnancy: Factors influencing efficacy. Obstet. Gynecol. 1999, 93, 983–986. [Google Scholar] [CrossRef] [PubMed]
- ul-Haq, N.; Hasnain, S.S.; Umar, M.; Abbas, Z.; Valenzuela-Silva, C.; Lopez-Saura, P. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. Vaccine 2003, 21, 3179–3185. [Google Scholar] [CrossRef]
- Chow, K.M.; Law, M.C.; Leung, C.B.; Szeto, C.C.; Li, P.K. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin. Pract. 2006, 103, c89–c93. [Google Scholar] [CrossRef]
- Estévez, Z.C.; Betancourt, A.A.; Muzio González, V.; Baile, N.F.; Silva, C.V.; Bernal, F.H.; Arias, E.P.; Delhanty Fernández, A.; Olazábal, N.M.; del Río Martín, A.; et al. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals 2007, 35, 115–122. [Google Scholar] [CrossRef]
- Young, K.M.; Gray, C.M.; Bekker, L.G. Is obesity a risk factor for vaccine non-responsiveness? PLoS ONE 2013, 8, e82779. [Google Scholar] [CrossRef][Green Version]
- Yang, S.; Tian, G.; Cui, Y.; Ding, C.; Deng, M.; Yu, C.; Xu, K.; Ren, J.; Yao, J.; Li, Y.; et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci. Rep. 2016, 6, 27251. [Google Scholar] [CrossRef][Green Version]
- Liu, F.; Guo, Z.; Dong, C. Influences of obesity on the immunogenicity of Hepatitis B vaccine. Hum. Vaccines Immunother. 2017, 13, 1014–1017. [Google Scholar] [CrossRef][Green Version]
- Kwon, Y.; Jeong, S.J. Association between Body Mass Index and Hepatitis B antibody seropositivity in children. Korean J. Pediatr. 2019, 62, 416–421. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Zhao, Y.L.; Pan, L.L.; Hao, Z.Y.; Jin, F.; Zhang, Y.H.; Li, M.J.; Zhang, X.J.; Han, B.H.; Zhou, H.S.; Ma, T.L.; et al. Immune response to different types of hepatitis B vaccine booster doses 2–32 years after the primary immunization schedule and its influencing factors. Int. J. Infect. Dis. 2020, 93, 62–67. [Google Scholar] [CrossRef] [PubMed]
- Joshi, S.S.; Davis, R.P.; Ma, M.M.; Tam, E.; Cooper, C.L.; Ramji, A.; Kelly, E.M.; Jayakumar, S.; Swain, M.G.; Jenne, C.N.; et al. Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD). NPJ Vaccines 2021, 6, 9. [Google Scholar] [CrossRef] [PubMed]
- Kulkarni, P.S.; Raut, S.K.; Patki, P.S.; Phadke, M.A.; Jadhav, S.S.; Kapre, S.V.; Dhorje, S.P.; Godse, S.R. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine 2006, 24, 3457–3460. [Google Scholar] [CrossRef] [PubMed]
- Kabir, A.; Lotfi, S.; Farsi, F.; Pazouki, A. Impact of body mass index on immunogenicity of hepatitis B vaccine in bariatric surgery candidates: A retrospective study. Diabetes Metab. Syndr. 2021, 15, 102254. [Google Scholar] [CrossRef]
- Middleman, A.B.; Anding, R.; Tung, C. Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics 2010, 125, e508-12. [Google Scholar] [CrossRef]
- Ozdemir, R.; Canpolat, F.E.; Yurttutan, S.; Oncel, M.Y.; Erdeve, O.; Dilmen, U. Effect of needle length for response to hepatitis B vaccine in macrosomic neonates: A prospective randomized study. Vaccine 2012, 30, 3155–3158. [Google Scholar] [CrossRef][Green Version]
- Sheridan, P.A.; Paich, H.A.; Handy, J.; Karlsson, E.A.; Hudgens, M.G.; Sammon, A.B.; Holland, L.A.; Weir, S.; Noah, T.L.; Beck, M.A. Obesity is associated with impaired immune response to influenza vaccination in humans. Int. J. Obes. 2012, 36, 1072–1077. [Google Scholar] [CrossRef][Green Version]
- Sperling, R.S.; Engel, S.M.; Wallenstein, S.; Kraus, T.A.; Garrido, J.; Singh, T.; Kellerman, L.; Moran, T.M. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet. Gynecol. 2012, 119, 631–639. [Google Scholar] [CrossRef][Green Version]
- Segerstrom, S.C.; Hardy, J.K.; Evans, D.R.; Greenberg, R.N. Vulnerability, distress, and immune response to vaccination in older adults. Brain Behav. Immun. 2012, 26, 747–753. [Google Scholar] [CrossRef][Green Version]
- Kuo, H.; Shapiro, J.R.; Dhakal, S.; Morgan, R.; Fink, A.L.; Lui, H.; Westerbeck, J.W.; Sylvia, K.E.; Park, H.S.; Ursin, R.L.; et al. Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers. Vaccine 2021, 40, 1634–1642. [Google Scholar] [CrossRef] [PubMed]
- Talbot, H.K.; Coleman, L.A.; Crimin, K.; Zhu, Y.; Rock, M.T.; Meece, J.; Shay, D.K.; Belongia, E.A.; Griffin, M.R. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 2012, 30, 3937–3943. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Clarke, M.; Goodchild, L.M.; Evans, S.; Giles, L.C.; Sullivan, S.G.; Barr, I.G.; Lambert, S.; Marshall, H. Body mass index and vaccine responses following influenza vaccination during pregnancy. Vaccine 2021, 39, 4864–4870. [Google Scholar] [CrossRef] [PubMed]
- Reuman, P.D.; Kubilis, P.; Hurni, W.; Brown, L.; Nalin, D. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 1997, 15, 1157–1161. [Google Scholar] [CrossRef]
- Van der Wielen, M.; Van Damme, P.; Chlibek, R.; Smetana, J.; von Sonnenburg, F. Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006, 24, 5509–5515. [Google Scholar] [CrossRef]
- Lim, J.; Song, Y.J.; Park, W.S.; Sohn, H.; Lee, M.S.; Shin, D.H.; Kim, C.B.; Kim, H.; Oh, G.J.; Ki, M. The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adults. Yonsei Med. J. 2014, 55, 126–131. [Google Scholar] [CrossRef][Green Version]
- Banga, N.; Guss, P.; Banga, A.; Rosenman, K.D. Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. Vaccine 2014, 32, 979–983. [Google Scholar] [CrossRef]
- Sauvageau, C.; Gilca, V.; Donken, R.; Fan, S.Y.; Ogilvie, G.; Dobson, S. The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9–13 year-old girls: Is it influenced by age, menarche status or body mass index? Vaccine 2019, 37, 7203–7206. [Google Scholar] [CrossRef]
- Eliakim, A.; Schwindt, C.; Zaldivar, F.; Casali, P.; Cooper, D.M. Reduced tetanus antibody titers in overweight children. Autoimmunity 2006, 39, 137–141. [Google Scholar] [CrossRef][Green Version]
- Pellini, R.; Venuti, A.; Pimpinelli, F.; Abril, E.; Blandino, G.; Campo, F.; Conti, L.; De Virgilio, A.; De Marco, F.; Di Domenico, E.G.; et al. Early Onset of SARS-CoV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. Vaccines 2021, 9, 685. [Google Scholar] [CrossRef]
- Watanabe, M.; Balena, A.; Tuccinardi, D.; Tozzi, R.; Risi, R.; Masi, D.; Caputi, A.; Rossetti, R.; Spoltore, M.E.; Filippi, V.; et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab. Res. Rev. 2022, 28, e3465. [Google Scholar] [CrossRef] [PubMed]
- Pellini, R.; Venuti, A.; Pimpinelli, F.; Abril, E.; Blandino, G.; Campo, F.; Conti, L.; De Virgilio, A.; De Marco, F.; Di Domenico, E.G.; et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine 2021, 36, 100928. [Google Scholar] [CrossRef] [PubMed]
- Grzelak, L.; Velay, A.; Madec, Y.; Gallais, F.; Staropoli, I.; Schmidt-Mutter, C.; Wendling, M.J.; Meyer, N.; Planchais, C.; Rey, D.; et al. Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2. J. Infect. Dis. 2021, 224, 983–988. [Google Scholar] [CrossRef]
- Simmonds, M.; Llewellyn, A.; Owen, C.G.; Woolacott, N. Predicting adult obesity from childhood obesity: A systematic review and meta-analysis. Obes. Rev. 2016, 17, 95–107. [Google Scholar] [CrossRef][Green Version]
- Madhavan, A.; Palappallil, D.S.; Balakrishnapanicker, J.; Asokan, A. Immune response to hepatitis B vaccine: An evaluation. Perspect. Clin. Res. 2021, 12, 209–215. [Google Scholar] [PubMed]
- Chiara, F.; Bartolucci, G.B.; Cattai, M.; Piazza, A.; Nicolli, A.; Buja, A.; Trevisan, A. Hepatitis B vaccination of adolescents: Significance of non-protective antibodies. Vaccine 2013, 32, 62–68. [Google Scholar] [CrossRef] [PubMed]
- Trevisan, A.; Frasson, C.; De Nuzzo, D.; Nicolli, A.; Scapellato, M.L. Significance of anti-HB levels below 10 IU/L after vaccination against hepatitis B in infancy or adolescence: An update in relation to sex. Hum. Vaccins Immunother. 2020, 16, 460–464. [Google Scholar] [CrossRef]
Males | Females | All | |
---|---|---|---|
(n = 815) | (n = 1370) | (n = 2185) | |
Age at recruitment (years ± SD) | 20.4 ± 0.9 | 20.2 ± 0.9 | 20.3 ± 0.9 |
Age 1st HBV vaccine (days ± SD) | 88.7 ± 20.2 | 89.1 ± 18.9 | 89.0 ± 19.4 |
Time between HBV vaccine (last dose) and analysis (years ± SD) | 19.4 ± 0.9 | 19.2 ± 0.9 | 19.3 ± 0.9 |
Age 1st dose MMR vaccine (years ± SD) | 1.4 ± 0.2 | 1.4 ± 0.1 | 1.4 ± 0.2 |
Age 2nd dose MMR vaccine (years ± SD) | 8.5 ± 2.1 | 8.3 ± 2.1 | 8.4 ± 2.1 |
Time between MMR vaccine (last dose) and analysis (years ± SD) | 11.9 ± 1.9 | 11.9 ± 2.0 | 11.9 ± 2.0 |
Weight (kg ± SD) | 73.0 ± 9.8 | 58.3 ± 8.5 | 63.8 ± 11.4 |
Height (cm ± SD) | 179.9 ± 6.5 | 166.6 ± 6.0 | 171.6 ± 9.0 |
BMI (kg/m2 ± SD) | 22.5 ± 2.6 | 21.0 ± 2.7 | 21.6 ± 2.7 |
Underweight * (%) | 31 (3.8) | 208 (15.2) | 239 (10.9) |
Normal weight (%) | 664 (81.5) | 1072 (78.2) | 1736 (79.5) |
Overweight (%) | 113 (13.9) | 78 (5.7) | 191 (8.7) |
Obesity ** (%) | 7 (0.9) | 12 (0.9) | 19 (0.9) |
Measles | Mumps | Rubella | Hepatitis | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | (%) | p | n | (%) | p | n | (%) | p | n | (%) | p | |
Males | 219 | 26.9 | 0.195 | 110 | 13.5 | 0.525 | 44 | 5.4 | 0.051 | 407 | 49.9 | 0.471 |
Females | 334 | 24.4 | 172 | 12.6 | 50 | 3.7 | 706 | 51.5 | ||||
Normal weight | 445 | 25.6 | 0.545 | 225 | 13.0 | 0.626 | 77 | 4.4 | 0.134 | 894 | 51.5 | 0.485 |
Underweight * | 54 | 22.6 | 35 | 14.6 | 5 | 2.1 | 120 | 50.2 | ||||
Overweight | 51 | 26.7 | 20 | 10.5 | 12 | 6.3 | 88 | 46.1 | ||||
Obesity ** | 3 | 15.8 | 2 | 10.5 | 0 | 0.0 | 11 | 57.9 |
Measles | Mumps | Rubella | Hepatitis | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AOR | (95% CI) | AOR | (95% CI) | AOR | (95% CI) | AOR | (95% CI) | |||||
Male sex | 1.09 | 0.88 | 1.33 | 1.15 | 0.88 | 1.49 | 1.39 | 0.91 | 2.14 | 0.97 | 0.81 | 1.16 |
BMI (ref. Normal weight) | ||||||||||||
Underweight * | 0.86 | 0.62 | 1.20 | 1.20 | 0.81 | 1.77 | 0.49 | 0.20 | 1.25 | 0.92 | 0.70 | 1.21 |
Overweight | 1.07 | 0.76 | 1.50 | 0.78 | 0.48 | 1.28 | 1.31 | 0.69 | 2.49 | 0.81 | 0.60 | 1.10 |
Obesity ** | 0.59 | 0.17 | 2.04 | 0.79 | 0.18 | 3.47 | - | - | - | 1.26 | 0.50 | 3.16 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fonzo, M.; Nicolli, A.; Maso, S.; Carrer, L.; Trevisan, A.; Bertoncello, C. Body Mass Index and Antibody Persistence after Measles, Mumps, Rubella and Hepatitis B Vaccinations. Vaccines 2022, 10, 1152. https://doi.org/10.3390/vaccines10071152
Fonzo M, Nicolli A, Maso S, Carrer L, Trevisan A, Bertoncello C. Body Mass Index and Antibody Persistence after Measles, Mumps, Rubella and Hepatitis B Vaccinations. Vaccines. 2022; 10(7):1152. https://doi.org/10.3390/vaccines10071152
Chicago/Turabian StyleFonzo, Marco, Annamaria Nicolli, Stefano Maso, Lorenzo Carrer, Andrea Trevisan, and Chiara Bertoncello. 2022. "Body Mass Index and Antibody Persistence after Measles, Mumps, Rubella and Hepatitis B Vaccinations" Vaccines 10, no. 7: 1152. https://doi.org/10.3390/vaccines10071152